-
Media Release
Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
-
Media Release
Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
-
Media Release
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
-
Media Release
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
-
Media Release
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
-
Media Release
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
-
Media Release
Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-
Media Release
Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-
Media Release
Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
-
Media Release
Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma